{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:10:50Z","timestamp":1791947450007,"version":"4.3.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"DOI":"10.1182\/bloodadvances.2026020672","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:56:37Z","timestamp":1780516597000},"page":"6845-6848","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Are statins interferon\u2019s best friends? Mechanistic insights"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-386X","authenticated-orcid":false,"given":"Giacomo Maria","family":"Cerreto","sequence":"first","affiliation":[{"name":"1Human Anatomy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carubbi","sequence":"additional","affiliation":[{"name":"1Human Anatomy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vitale","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-0428","authenticated-orcid":false,"given":"Elena","family":"Masselli","sequence":"additional","affiliation":[{"name":"1Human Anatomy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy"},{"name":"3Hematology and Bone Marrow Transplant Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"23","key":"2026101311212394800_bib1","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1182\/bloodadvances.2025017016","article-title":"Statins enhance the efficacy of pegylated IFN-\u03b12 in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"9","author":"Davidsen","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026101311212394800_bib2","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/bloodadvances.2026019625","article-title":"Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners","volume":"10","author":"Hasselbalch","year":"2026","journal-title":"Blood Adv"},{"issue":"14","key":"2026101311212394800_bib3","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2026101311212394800_bib4","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/bloodadvances.2025018724","article-title":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"issue":"6","key":"2026101311212394800_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2026.2639642","article-title":"Ruxolitinib and heart failure outcomes among patients with myelofibrosis","volume":"67","author":"Leiva","year":"2026","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2026101311212394800_bib6","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/biomedicines12112435","article-title":"Reversal of atherosclerotic plaque growth and vulnerability: effects of lipid-modifying and anti-inflammatory therapeutic agents","volume":"12","author":"Papafaklis","year":"2024","journal-title":"Biomedicines"},{"issue":"19","key":"2026101311212394800_bib7","doi-asserted-by":"crossref","first-page":"e008657","DOI":"10.1161\/JAHA.118.008657","article-title":"Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: a systematic review and meta-analysis","volume":"7","author":"Salata","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"2026101311212394800_bib8","doi-asserted-by":"crossref","first-page":"11343","DOI":"10.3390\/ijms222111343","article-title":"Platelets contribution to thrombin generation in Philadelphia-negative myeloproliferative neoplasms: the \u201ccirculating wound\u201d model","volume":"22","author":"Lucchesi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2026101311212394800_bib9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3324\/haematol.2023.283958","article-title":"New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-a alter the natural history of the disease?","volume":"110","author":"Pasquier","year":"2024","journal-title":"Haematologica"},{"issue":"30","key":"2026101311212394800_bib10","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-\u03b1 in BCR-ABL-expressing cells","volume":"276","author":"Mayer","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"2026101311212394800_bib11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-022-29381-7","article-title":"Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms","volume":"13","author":"Saleiro","year":"2022","journal-title":"Nat Commun"},{"issue":"23","key":"2026101311212394800_bib12","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/s41388-022-02329-3","article-title":"Role of p38 MAP kinase in cancer stem cells and metastasis","volume":"41","author":"Kudaravalli","year":"2022","journal-title":"Oncogene"},{"issue":"7","key":"2026101311212394800_bib13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.leu.2401447","article-title":"A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation","volume":"13","author":"Birkenkamp","year":"1999","journal-title":"Leukemia"},{"issue":"28","key":"2026101311212394800_bib14","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41388-019-0813-7","article-title":"Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation","volume":"38","author":"Stetka","year":"2019","journal-title":"Oncogene"},{"issue":"6","key":"2026101311212394800_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-\u03b1 targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp Hematol"},{"issue":"1","key":"2026101311212394800_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1756-9966-29-127","article-title":"Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho\/Rho-associated coiled-coil-containing protein kinase pathway","volume":"29","author":"Kidera","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2026101311212394800_bib17","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1038\/cddis.2013.44","article-title":"HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway","volume":"4","author":"Qi","year":"2013","journal-title":"Cell Death Dis"},{"issue":"4","key":"2026101311212394800_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1165\/rcmb.2007-0012OC","article-title":"Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts","volume":"37","author":"Carlin","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"2026101311212394800_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/1535-7163.MCT-16-0499","article-title":"Simvastatin-induced apoptosis in osteosarcoma cells: a key role of rhoa-ampk\/p38 mapk signaling in antitumor activity","volume":"16","author":"Kamel","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2026101311212394800_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"2026101311212394800_bib21","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1016\/j.yexcr.2007.08.007","article-title":"Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity","volume":"313","author":"Thyrell","year":"2007","journal-title":"Exp Cell Res"},{"key":"2026101311212394800_bib22","doi-asserted-by":"crossref","first-page":"101352","DOI":"10.1016\/j.drup.2026.101352","article-title":"IFN\u03b12b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms","volume":"85","author":"Fang","year":"2026","journal-title":"Drug Resist Updat"},{"key":"2026101311212394800_bib23","doi-asserted-by":"crossref","first-page":"114024","DOI":"10.1016\/j.biopha.2022.114024","article-title":"Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3\/CPT1 pathway","volume":"157","author":"Zheng","year":"2023","journal-title":"Biomed Pharmacother"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6845\/2594414\/blooda_adv-2026-020672-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6845\/2594414\/blooda_adv-2026-020672-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:21:32Z","timestamp":1791904892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6845\/568809\/Are-statins-interferon-s-best-friends-Mechanistic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020672","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,10,13]]}}}